Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2018

01-10-2018 | Original article

Low serum phosphate is associated with ischemic stroke in hemodialysis patients

Authors: Tsang-Shan Chen, Chao-Hung Chen, Chien-An Chen, Li-Ping Chou, Chi-Chu Liu

Published in: Clinical and Experimental Nephrology | Issue 5/2018

Login to get access

Abstract

Background

Hemodialysis patients have a high incidence of ischemic stroke. However, the association between serum phosphate levels and ischemic stroke is controversial among hemodialysis patients. The present study is used to evaluate whether serum phosphate levels are associated with ischemic stroke among patients undergoing hemodialysis.

Methods

A total of 84 hemodialysis patients were followed up for 8 years. Data collection included chart reviews and assessments of laboratory records. The ischemic stroke diagnosis was made on the basis of history, physical examination and neuroimaging (computed tomography and/or magnetic resonance imaging) by neurologists. Cox proportional hazard regression models were used to analyze the data.

Results

During the follow-up period, 29 patients experienced ischemic stroke. According to Cox proportional hazard regression analysis, the risk of ischemic stroke decreased by 45.5% for each 1-mg/dL increase in averaged serum phosphate (HR 0.545, p = 0.011). The risk of ischemic stroke increased by 4.3% for each 1-year increase in age (HR 1.043, p = 0.018). The risk of ischemic stroke increased by 1.1% increase for each 103/μL increase in averaged blood platelet (HR 1.011, p = 0.009). The risk of ischemic stroke in patients with averaged serum phosphate < 4.5 mg/dL increased 3.40-fold more than patients with averaged serum phosphate ≥ 4.5 mg/dL (HR 3.400, p = 0.025).

Conclusions

Low serum phosphate is a risk factor for developing ischemic stroke in hemodialysis patients. The results suggest that managing serum phosphate ≥ 4.5 mg/dL among hemodialysis patients may reduce the risk of ischemic stroke.
Literature
1.
go back to reference Herrington W, Haynes R, Staplin N, Emberson J, Baigent C, Landray M. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial. 2015;28:35–47.CrossRef Herrington W, Haynes R, Staplin N, Emberson J, Baigent C, Landray M. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial. 2015;28:35–47.CrossRef
2.
go back to reference Arnold J, Sims D, Ferro CJ. Modulation of stroke risk in chronic kidney disease. Clin Kidney J. 2016;9:29–38.CrossRef Arnold J, Sims D, Ferro CJ. Modulation of stroke risk in chronic kidney disease. Clin Kidney J. 2016;9:29–38.CrossRef
3.
go back to reference Power A. Stroke in dialysis and chronic kidney disease. Blood Purif. 2013;36:179 – 83.CrossRef Power A. Stroke in dialysis and chronic kidney disease. Blood Purif. 2013;36:179 – 83.CrossRef
4.
go back to reference Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.CrossRef Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.CrossRef
5.
go back to reference Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009;4:1136–9.CrossRef Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009;4:1136–9.CrossRef
6.
go back to reference Weiner DE, Sarnak MJ. A decade after the KDOQI CKD guidelines: impact on the cardiovascular disease-CKD paradigm. Am J Kidney Dis. 2012;60:710–2.CrossRef Weiner DE, Sarnak MJ. A decade after the KDOQI CKD guidelines: impact on the cardiovascular disease-CKD paradigm. Am J Kidney Dis. 2012;60:710–2.CrossRef
7.
go back to reference Ruan L, Chen W, Srinivasan SR, Xu J, Toprak A, Berenson GS. Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). Am J Cardiol. 2010;106:793–7.CrossRef Ruan L, Chen W, Srinivasan SR, Xu J, Toprak A, Berenson GS. Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). Am J Cardiol. 2010;106:793–7.CrossRef
8.
go back to reference Bugnicourt JM, Chillon JM, Massy ZA, Canaple S, Lamy C, Deramond H, et al. High prevalence of intracranial artery calcification in stroke patients with CKD: a retrospective study. Clin J Am Soc Nephrol. 2009;4:284 – 90.CrossRef Bugnicourt JM, Chillon JM, Massy ZA, Canaple S, Lamy C, Deramond H, et al. High prevalence of intracranial artery calcification in stroke patients with CKD: a retrospective study. Clin J Am Soc Nephrol. 2009;4:284 – 90.CrossRef
9.
go back to reference Chen XY, Lam WW, Ng HK, Fan YH, Wong KS. The frequency and determinants of calcification in intracranial arteries in Chinese patients who underwent computed tomography examinations. Cerebrovasc Dis. 2006;21:91 – 7.CrossRef Chen XY, Lam WW, Ng HK, Fan YH, Wong KS. The frequency and determinants of calcification in intracranial arteries in Chinese patients who underwent computed tomography examinations. Cerebrovasc Dis. 2006;21:91 – 7.CrossRef
10.
go back to reference Li JW, Xu C, Xiao YB. Serum phosphate concentration and incidence of stroke: a systemic review and meta-analysis. Neurol Sci. 2014;35:1877–82.CrossRef Li JW, Xu C, Xiao YB. Serum phosphate concentration and incidence of stroke: a systemic review and meta-analysis. Neurol Sci. 2014;35:1877–82.CrossRef
11.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201 National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201
12.
go back to reference Wetmore JB, Ellerbeck EF, Mahnken JD, Phadnis MA, Rigler SK, Spertus JA, et al. Stroke and the “stroke belt” in dialysis: contribution of patient characteristics to ischemic stroke rate and its geographic variation. J Am Soc Nephrol. 2013;24:2053–61.CrossRef Wetmore JB, Ellerbeck EF, Mahnken JD, Phadnis MA, Rigler SK, Spertus JA, et al. Stroke and the “stroke belt” in dialysis: contribution of patient characteristics to ischemic stroke rate and its geographic variation. J Am Soc Nephrol. 2013;24:2053–61.CrossRef
13.
go back to reference Du J, Wang Q, He B, Liu P, Chen JY, Quan H, et al. Association of mean platelet volume and platelet count with the development and prognosis of ischemic and hemorrhagic stroke. Int J Lab Hematol. 2016;38:233–9.CrossRef Du J, Wang Q, He B, Liu P, Chen JY, Quan H, et al. Association of mean platelet volume and platelet count with the development and prognosis of ischemic and hemorrhagic stroke. Int J Lab Hematol. 2016;38:233–9.CrossRef
14.
go back to reference Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, Patel RK, et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke. 2015;46:2477–81.CrossRef Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, Patel RK, et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke. 2015;46:2477–81.CrossRef
15.
go back to reference Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662–8.CrossRef Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662–8.CrossRef
16.
go back to reference Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196 – 203.CrossRef Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196 – 203.CrossRef
17.
go back to reference Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788–93.CrossRef Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788–93.CrossRef
18.
go back to reference Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119–27.CrossRef Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119–27.CrossRef
19.
go back to reference Kang K. Serum calcium and phosphate concentrations and intracranial atherosclerosis. Atherosclerosis. 2014;232:249–53.CrossRef Kang K. Serum calcium and phosphate concentrations and intracranial atherosclerosis. Atherosclerosis. 2014;232:249–53.CrossRef
20.
go back to reference Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2008;156:556–63.CrossRef Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2008;156:556–63.CrossRef
21.
go back to reference Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, et al. Mineral metabolism markers are associated with myocardial infarction and hemorrhagic stroke but not ischemic stroke in hemodialysis patients: a longitudinal study. PLoS One. 2014;9:e114678.CrossRef Tagawa M, Hamano T, Nishi H, Tsuchida K, Hanafusa N, Fukatsu A, et al. Mineral metabolism markers are associated with myocardial infarction and hemorrhagic stroke but not ischemic stroke in hemodialysis patients: a longitudinal study. PLoS One. 2014;9:e114678.CrossRef
22.
go back to reference Yamada S, Tsuruya K, Taniguchi M, Tokumoto M, Fujisaki K, Hirakata H, et al. Association between serum phosphate levels and stroke risk in patients undergoing hemodialysis: the Q-cohort study. Stroke. 2016;47:2189–96.CrossRef Yamada S, Tsuruya K, Taniguchi M, Tokumoto M, Fujisaki K, Hirakata H, et al. Association between serum phosphate levels and stroke risk in patients undergoing hemodialysis: the Q-cohort study. Stroke. 2016;47:2189–96.CrossRef
23.
go back to reference Terrier N, Senecal L, Dupuy AM, Jaussent I, Delcourt C, Leray H, et al. Association between novel indices of malnutrition-inflammation complex syndrome and cardiovascular disease in hemodialysis patients. Hemodial Int. 2005;9:159–68.CrossRef Terrier N, Senecal L, Dupuy AM, Jaussent I, Delcourt C, Leray H, et al. Association between novel indices of malnutrition-inflammation complex syndrome and cardiovascular disease in hemodialysis patients. Hemodial Int. 2005;9:159–68.CrossRef
24.
go back to reference Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol. 2003;14:2623–31.CrossRef Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol. 2003;14:2623–31.CrossRef
25.
go back to reference Sozio SM, Coresh J, Jaar BG, Fink NE, Plantinga LC, Armstrong PA, et al. Inflammatory markers and risk of cerebrovascular events in patients initiating dialysis. Clin J Am Soc Nephrol. 2011;6:1292–300.CrossRef Sozio SM, Coresh J, Jaar BG, Fink NE, Plantinga LC, Armstrong PA, et al. Inflammatory markers and risk of cerebrovascular events in patients initiating dialysis. Clin J Am Soc Nephrol. 2011;6:1292–300.CrossRef
26.
go back to reference Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol. 2004;15:733–42.CrossRef Beddhu S, Pappas LM, Ramkumar N, Samore MH. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol. 2004;15:733–42.CrossRef
Metadata
Title
Low serum phosphate is associated with ischemic stroke in hemodialysis patients
Authors
Tsang-Shan Chen
Chao-Hung Chen
Chien-An Chen
Li-Ping Chou
Chi-Chu Liu
Publication date
01-10-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 5/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1578-y

Other articles of this Issue 5/2018

Clinical and Experimental Nephrology 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.